Details der Publikation - Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan

Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan

Background Identifying predictive factors for coronavirus disease 2019 (COVID-19) is crucial for risk stratification and intervention. Kidney dysfunction contributes to the severity of various infectious diseases. However, the association between on-admission kidney dysfunction and the clinical outcome in COVID-19 patients is unclear. Methods This study was a multicenter retrospective observational cohort study of COVID-19 patients, diagnosed by polymerase chain reaction. We retrospectively analyzed 500 COVID-19 patients (mean age: 51 ± 19 years) admitted to eight hospitals in Japan. Kidney dysfunction was defined as a reduced estimated glomerular filtration rate (< 60 mL/min/1.73 $ m^{2} $) or proteinuria (≥ 1 + dipstick proteinuria) on admission. The primary composite outcome included in-hospital death, extracorporeal membrane oxygenation, mechanical ventilation (invasive and noninvasive methods), and intensive care unit (ICU) admission. Results Overall, 171 (34.2%) patients presented with on-admission kidney dysfunction, and the primary composite outcome was observed in 60 (12.0%) patients. Patients with kidney dysfunction showed higher rates of in-hospital death (12.3 vs. 1.2%), mechanical ventilation (13.5 vs. 4.0%), and ICU admission (18.1 vs. 5.2%) than those without it. Categorical and multivariate regression analyses revealed that kidney dysfunction was substantially associated with the primary composite outcome. Thus, on-admission kidney dysfunction was common in COVID-19 patients. Furthermore, it correlated significantly and positively with COVID-19 severity and mortality. Conclusions On-admission kidney dysfunction was associated with disease severity and poor short-term prognosis in patients with COVID-19. Thus, on-admission kidney dysfunction has the potential to stratify risks in COVID-19 patients..

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:26
Enthalten in:	Clinical and experimental nephrology - 26(2022), 10 vom: 03. Juni, Seite 974-981

Sprache:	Englisch

Beteiligte Personen:	Sato, Ryosuke [VerfasserIn] Matsuzawa, Yasushi [VerfasserIn] Ogawa, Hisao [VerfasserIn] Kimura, Kazuo [VerfasserIn] Tsuboi, Nobuo [VerfasserIn] Yokoo, Takashi [VerfasserIn] Okada, Hirokazu [VerfasserIn] Konishi, Masaaki [VerfasserIn] Kirigaya, Jin [VerfasserIn] Fukui, Kazuki [VerfasserIn] Tsukahara, Kengo [VerfasserIn] Shimizu, Hiroyuki [VerfasserIn] Iwabuchi, Keisuke [VerfasserIn] Yamada, Yu [VerfasserIn] Saka, Kenichiro [VerfasserIn] Takeuchi, Ichiro [VerfasserIn] Kashihara, Naoki [VerfasserIn] Tamura, Kouichi [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.88$jUrologie$jNephrologie
Themen:	COVID-19 Clinical outcome Kidney dysfunction

Anmerkungen:	© The Author(s), under exclusive licence to The Japanese Society of Nephrology 2022

doi:	10.1007/s10157-022-02240-x

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC213205651X

Internformat


LEADER	01000naa a22002652 4500
001	OLC213205651X
003	DE-627
005	20230506064918.0
007	cr uuu---uuuuu
008	230506s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10157-022-02240-x \|2 doi
035			\|a (DE-627)OLC213205651X
035			\|a (DE-He213)s10157-022-02240-x-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
082	0	4	\|a 610 \|q VZ
084			\|a 44.88$jUrologie$jNephrologie \|2 bkl
100	1		\|a Sato, Ryosuke \|e verfasserin \|4 aut
245	1	0	\|a Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to The Japanese Society of Nephrology 2022
520			\|a Background Identifying predictive factors for coronavirus disease 2019 (COVID-19) is crucial for risk stratification and intervention. Kidney dysfunction contributes to the severity of various infectious diseases. However, the association between on-admission kidney dysfunction and the clinical outcome in COVID-19 patients is unclear. Methods This study was a multicenter retrospective observational cohort study of COVID-19 patients, diagnosed by polymerase chain reaction. We retrospectively analyzed 500 COVID-19 patients (mean age: 51 ± 19 years) admitted to eight hospitals in Japan. Kidney dysfunction was defined as a reduced estimated glomerular filtration rate (< 60 mL/min/1.73 $ m^{2} $) or proteinuria (≥ 1 + dipstick proteinuria) on admission. The primary composite outcome included in-hospital death, extracorporeal membrane oxygenation, mechanical ventilation (invasive and noninvasive methods), and intensive care unit (ICU) admission. Results Overall, 171 (34.2%) patients presented with on-admission kidney dysfunction, and the primary composite outcome was observed in 60 (12.0%) patients. Patients with kidney dysfunction showed higher rates of in-hospital death (12.3 vs. 1.2%), mechanical ventilation (13.5 vs. 4.0%), and ICU admission (18.1 vs. 5.2%) than those without it. Categorical and multivariate regression analyses revealed that kidney dysfunction was substantially associated with the primary composite outcome. Thus, on-admission kidney dysfunction was common in COVID-19 patients. Furthermore, it correlated significantly and positively with COVID-19 severity and mortality. Conclusions On-admission kidney dysfunction was associated with disease severity and poor short-term prognosis in patients with COVID-19. Thus, on-admission kidney dysfunction has the potential to stratify risks in COVID-19 patients.
650		4	\|a Kidney dysfunction
650		4	\|a Clinical outcome
650		4	\|a COVID-19
700	1		\|a Matsuzawa, Yasushi \|4 aut
700	1		\|a Ogawa, Hisao \|4 aut
700	1		\|a Kimura, Kazuo \|4 aut
700	1		\|a Tsuboi, Nobuo \|4 aut
700	1		\|a Yokoo, Takashi \|4 aut
700	1		\|a Okada, Hirokazu \|4 aut
700	1		\|a Konishi, Masaaki \|4 aut
700	1		\|a Kirigaya, Jin \|4 aut
700	1		\|a Fukui, Kazuki \|4 aut
700	1		\|a Tsukahara, Kengo \|4 aut
700	1		\|a Shimizu, Hiroyuki \|4 aut
700	1		\|a Iwabuchi, Keisuke \|4 aut
700	1		\|a Yamada, Yu \|4 aut
700	1		\|a Saka, Kenichiro \|4 aut
700	1		\|a Takeuchi, Ichiro \|4 aut
700	1		\|a Kashihara, Naoki \|4 aut
700	1		\|a Tamura, Kouichi \|4 aut
773	0	8	\|i Enthalten in \|t Clinical and experimental nephrology \|d Springer Nature Singapore, 1997 \|g 26(2022), 10 vom: 03. Juni, Seite 974-981 \|h Online-Ressource \|w (DE-627)306646900 \|w (DE-600)1499111-1 \|w (DE-576)113948530 \|x 1437-7799 \|7 nnns
773	1	8	\|g volume:26 \|g year:2022 \|g number:10 \|g day:03 \|g month:06 \|g pages:974-981
856	4	0	\|u https://dx.doi.org/10.1007/s10157-022-02240-x \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_267
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2132
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.88$jUrologie$jNephrologie \|q VZ \|0 106410059 \|0 (DE-625)106410059
951			\|a AR
952			\|d 26 \|j 2022 \|e 10 \|b 03 \|c 06 \|h 974-981

Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände